))
Ryan Crisman of Umoja Biopharma — Building Manufacturing In-House at an Early Stage
Manage episode 481590700 series 3580470
Content provided by Executive Platforms. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Executive Platforms or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
In anticipation of the next edition of our long-running and successful Biomanufacturing World Summit series, we spoke with Ryan Crisman, the co-founder and Chief Technical Officer of Umoja Biopharma about the industry's current and future capacity challenges, and why Umoja chose to build its manufacturing in-house at an early stage, with some specific examples and references to Umoja’s new Colorado Laboratory & Innovative Manufacturing Building, which they call, ‘The CLIMB.’
We also discussed the issues of Talent and Leadership in a rapidly growing sector, and what organizations need to be doing individually and as a community to forge the next generation of medicine together. It is a fantastic and timely conversation about where biopharmaceutical manufacturers are today and where they need to get to in the near-future from the perspective of someone at the forefront of making that future a reality. Give this one a listen!
--
Ryan Crisman
Co-Founder and Chief Technical Officer
Umoja Biopharma
Ryan Crisman is the co-founder and Chief Technical Officer at Umoja Biopharma. Before starting Umoja in 2019, Ryan served as the Executive Director for the Gates Biomanufacturing Facility, where he was responsible for building out and staffing this protein and cell therapy CDMO. He was instrumental in growing the facility’s cGMP capabilities and delivering many first in human therapeutic products to patients. While at Juno Therapeutics, Ryan led the JCAR017 CMC program and was the Head of Late Stage Process Development. He has also held scientific leadership positions at Zymogenetics and CMC Biologics.
Crisman holds a Ph.D. in Chemical Engineering from the University of Colorado, Boulder, and a bachelor’s degree in Chemical Engineering from Washington State University.
--
Umoja Biopharma’s world-class team of scientists, researchers, and drug development experts are united by their shared goal of unlocking the true potential of CAR T cell therapies. Their deep experience, meticulous attention to detail, and innovative spirit drive us in our mission to extend the benefits of immunotherapy to every patient bearing the burden of cancer.
276 episodes
Share
